Leukemia & Lymphoma, Volume 64, Issue 5 (2023)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 64, Issue 5 (2023)

See all volumes and issues
Vol 65, 2024 Volume 64, 2023 Vol 63, 2022 Vol 62, 2021 Vol 61, 2020 Vol 60, 2019 Vol 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Vol 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs Download issue

Commentaries

Article Commentary
Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?
Tadeusz Robak
Pages: 907-909
Published online: 10 Mar 2023
First Page PreviewforIs this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia? | Full Text | References | PDF (412.1 KB) | EPUB
  • 237 Views
  • 2 CrossRef citations
  • 0Altmetric
Article Commentary
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies
Thomas W. LeBlanc
Pages: 910-912
Published online: 11 May 2023
First Page PreviewforMoving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies | Full Text | References | PDF (303.5 KB) | EPUB
  • 134 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Articles

Article
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study
Julio Bravo, Patricia Baltasar Tello, Esther González Garcia, Eduardo Ríos Herranz, Angel Ramirez Páyer, María José Terol Castera, Diana Champ, Angeles Medina Perez, Mercedes Gironella, Miguel Fernández Zarzoso, Rafael Forés, Julio Delgado, José A. Garcia-Marco, on behalf of the GABRIELL Study Group/Investigators & on behalf of the GABRIELL Study Group/Investigators
Pages: 913-926
Published online: 31 May 2023
AbstractforObinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 218 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia
Ryan D. Cassaday, Lucas C. Zarling, Kelsey-Leigh A. Garcia, Olga Sala-Torra, Philip A. Stevenson, Christen H. Martino, Yajuan J. Liu, Min Fang, Mary-Elizabeth M. Percival, Anna B. Halpern, Pamela S. Becker, Vivian G. Oehler, Andrei R. Shustov, Jason P. Cooper, Johnnie J. Orozco, Paul C. Hendrie, Roland B. Walter, Jerald P. Radich, Lorinda A. Soma & Elihu H. Estey
Pages: 927-937
Published online: 20 Mar 2023
AbstractforPhase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 446 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML
Ellen K. Ritchie, David Cella, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, Cristina Ivanescu, Bhavik J. Pandya & Manasee V. Shah
Pages: 938-950
Published online: 05 Apr 2023
AbstractforPatient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 2281 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access
Article
RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia
Jinyan Xiao, Jundan Xie, Biqi Zhou, Yujie Liu, Jing Lu, Airui Jiang, Hong Yao, Qiaocheng Qiu, Zixuan Ding, Shengli Xue, Xiaowen Tang, Huiying Qiu, Suning Chen, Hongjie Shen, Depei Wu & Yang Xu
Pages: 951-961
Published online: 24 Mar 2023
AbstractforRUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia | Full Text | References | PDF (2.3 MB) | EPUB | Supplemental
  • 171 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia
Moaath K. Mustafa Ali, Matthew T. Williams, Elizabeth M. Corley, Fahad AlKaabba & Sandrine Niyongere
Pages: 962-971
Published online: 12 Apr 2023
AbstractforImpact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
  • 2634 Views
  • 3 CrossRef citations
  • 0Altmetric
Open Access
Article
Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group
Maximiliano Ramia de Cap, Leo P. Wu, Christian Hirt, German A. Pihan, Sanjay S. Patel, Wayne Tam, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Philipp W. Raess, Alexa Siddon, Damodaran Narayanan, Elizabeth A. Morgan, Geraldine S. Pinkus, Emily F. Mason, Eric D. Hsi, Heesun J. Rogers, Laura Toth, Kathryn Foucar, Stephanie N. Hurwitz, Adam Bagg, Anton Rets, Tracy I. George, Attilio Orazi, Daniel A. Arber, Robert P. Hasserjian, Olga K. Weinberg & for the Bone Marrow Pathology Group
Pages: 972-980
Published online: 24 Mar 2023
AbstractforMyeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
  • 473 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value
Ninna Brix, Christoph Kessel, Dirk Foell, Henrik Hasle, Birgitte Klug Albertsen, Niels Henrik Bruun, Søren Hagstrøm & Troels Herlin
Pages: 981-989
Published online: 17 Apr 2023
AbstractforPhagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value | Full Text | References | PDF (1.1 MB) | EPUB | Supplemental
  • 166 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents
Michelle Y. Zhang, Megan Othus, Carole Shaw, Kelda G. Schonhoff, Anna B. Halpern, Jacob Appelbaum, Paul C. Hendrie, Roland B. Walter, Elihu H. Estey & Mary-Elizabeth M. Percival
Pages: 990-996
Published online: 08 Mar 2023
AbstractforPoor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents | Full Text | References | PDF (1 MB) | EPUB
  • 120 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia
Lennart Hardell, Michael Carlberg, Marie Nordström & Mikael Eriksson
Pages: 997-1004
Published online: 20 Mar 2023
AbstractforExposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia | Full Text | References | PDF (887.8 KB) | EPUB
  • 408 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study
Toby A. Eyre, Lisa M. Hess, Tomoko Sugihara, Dan He, Manoj Khanal, John M. Pagel, Richard A. Walgren, Paolo B. Abada, Heiko Konig, Lindsey E. Roeker & Anthony Mato
Pages: 1005-1016
Published online: 29 Mar 2023
AbstractforClinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 4255 Views
  • 7 CrossRef citations
  • 0Altmetric
Open Access
Article
Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial
Tycel Phillips, Kristen Migliaccio-Walle, Kristina S. Yu, Brian Bloudek, Nicholas Liu, Michelle Fanale & John M. Burke
Pages: 1017-1025
Published online: 19 Apr 2023
AbstractforEstimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial | Full Text | References | PDF (1.4 MB) | EPUB
  • 1465 Views
  • 3 CrossRef citations
  • 0Altmetric
Open Access
Article
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort
Prashasti Agrawal, Kevin A. David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean A. Vendiola, Nasheed Hossain, Mazie Tsang, Ajay Major, Maher K. Gandhi, Colm Keane, David A. Bond, Matthew Folstad, Julie Chang, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A. Goldlust, Rahul Matnani, Pallavi Kumar, Thomas A. Ollila, Johnny Cai, Stephen E. Spurgeon, Alex G. Sieg, Joseph Cleveland, Narendranath Epperla, Reem Karmali, Seema Naik, Sonali M. Smith, James L. Rubenstein, Brad S. Kahl, Amy Chadburn, Andrew M. Evens & Peter Martin
Pages: 1026-1034
Published online: 24 Mar 2023
AbstractforEBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort | Full Text | References | PDF (1.5 MB) | EPUB
  • 459 Views
  • 3 CrossRef citations
  • 0Altmetric

Letters to the Editor

Letter to the Editor
Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data
Christopher T. Su, Jason C. Chen & Jeremy B. Sussman
Pages: 1035-1039
Published online: 16 Mar 2023
First Page PreviewforVirtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data | Full Text | References | PDF (1.1 MB) | EPUB
  • 97 Views
  • 1 CrossRef citations
  • 0Altmetric
Letter to the Editor
The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia
Mohammad Ammad Ud Din, Hassan Saeed, Moazzam Shahzad, Hania Liaqat & Kendra Sweet
Pages: 1040-1044
Published online: 20 Mar 2023
First Page PreviewforThe impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia | Full Text | References | PDF (715.6 KB) | EPUB | Supplemental
  • 70 Views
  • 1 CrossRef citations
  • 0Altmetric
Letter to the Editor
Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia
Ross T. Salvaris, Benjamin Allanson & Chan Y. Cheah
Pages: 1045-1049
Published online: 24 Mar 2023
First Page PreviewforUsing next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia | Full Text | References | PDF (1.9 MB) | EPUB
  • 126 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter to the Editor
Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center
Alicia McGhie, Jenessa Lee, Alessandra Ferrajoli & Adam J. DiPippo
Pages: 1050-1053
Published online: 08 Mar 2023
First Page PreviewforTolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center | Full Text | References | PDF (521.4 KB) | EPUB | Supplemental
  • 353 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter to the Editor
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir
Tamar Tadmor, Guy Melamed, Tal Patalon, Hilel Alapi & Lior Rokach
Pages: 1054-1056
Published online: 13 Mar 2023
First Page PreviewforRebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir | Full Text | References | PDF (305.8 KB) | EPUB
  • 261 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter to the Editor
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms
Noam E. Kopmar, Ted Gooley, Niall Curley, Kathryn Russell, Carole Shaw, Kelda Schonhoff, John Lim, Anna B. Halpern, Roland B. Walter, Bart L. Scott, Jacob Appelbaum, Paul C. Hendrie, Elihu H. Estey & Mary-Elizabeth M. Percival
Pages: 1057-1059
Published online: 09 Mar 2023
First Page PreviewforResults from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms | Full Text | References | PDF (633.9 KB) | EPUB | Supplemental
  • 130 Views
  • 0 CrossRef citations
  • 0Altmetric

Corrections

Correction
Correction
Page: 1060
Published online: 26 Feb 2022
CitationforCorrection | Full Text | PDF (94 KB) | EPUB
  • 549 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Correction
Correction
Page: 1061
Published online: 08 Sep 2022
CitationforCorrection | Full Text | PDF (93.1 KB) | EPUB
  • 504 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Explore articles

Explore the most recently published articles

High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera
Ivan Krecak et al.
Letter to the Editor | Published online: 20 Jun 2024
Experience of using venetoclax in relapsed T- cell lymphoma
Jasmine Zain et al.
Letter to the Editor | Published online: 17 Jun 2024
Therapy-related myeloid neoplasms with single-hit TP53 mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts
Taylor Zak et al.
Article | Published online: 17 Jun 2024
Polycythemia vera: past, present and future
Ami B. Patel et al.
Review Article | Published online: 13 Jun 2024
View all latest articles